ECSP045067A - Sales de alendronato farmaceuticamente aceptables en forma amorfa - Google Patents

Sales de alendronato farmaceuticamente aceptables en forma amorfa

Info

Publication number
ECSP045067A
ECSP045067A EC2004005067A ECSP045067A ECSP045067A EC SP045067 A ECSP045067 A EC SP045067A EC 2004005067 A EC2004005067 A EC 2004005067A EC SP045067 A ECSP045067 A EC SP045067A EC SP045067 A ECSP045067 A EC SP045067A
Authority
EC
Ecuador
Prior art keywords
pharmaceutically acceptable
amorphy
acceptable alendronate
salts
alendronate salts
Prior art date
Application number
EC2004005067A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9924125&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP045067(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of ECSP045067A publication Critical patent/ECSP045067A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839—Polyphosphonic acids
    • C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una sal de alendronato farmacéuticamente aceptable en forma amorfa.
EC2004005067A 2001-10-18 2004-04-16 Sales de alendronato farmaceuticamente aceptables en forma amorfa ECSP045067A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0125081A GB2383042A (en) 2001-10-18 2001-10-18 Amorphous alendronate sodium

Publications (1)

Publication Number Publication Date
ECSP045067A true ECSP045067A (es) 2004-07-23

Family

ID=9924125

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005067A ECSP045067A (es) 2001-10-18 2004-04-16 Sales de alendronato farmaceuticamente aceptables en forma amorfa

Country Status (21)

Country Link
US (1) US7112577B2 (es)
EP (1) EP1436303B1 (es)
JP (1) JP4490100B2 (es)
KR (1) KR20040053186A (es)
AT (1) ATE338761T1 (es)
AU (1) AU2002334200B2 (es)
BR (1) BR0213398A (es)
CA (1) CA2463815C (es)
CL (1) CL2004001372A1 (es)
DE (1) DE60214576T2 (es)
EC (1) ECSP045067A (es)
ES (1) ES2271375T3 (es)
GB (1) GB2383042A (es)
IL (1) IL161360A0 (es)
MX (1) MXPA04003549A (es)
NZ (1) NZ532292A (es)
PT (1) PT1436303E (es)
RU (1) RU2334751C2 (es)
TN (1) TNSN04067A1 (es)
WO (1) WO2003033508A1 (es)
ZA (1) ZA200403024B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100897837B1 (ko) * 2001-12-24 2009-05-15 테바 파마슈티컬 인더스트리즈 리미티드 분말 또는 과립 물질의 압착된 환상체 내에 싸인 활성성분의 코어 정제를 갖는 제형과, 이의 제조 방법 및 툴링
US20040052843A1 (en) * 2001-12-24 2004-03-18 Lerner E. Itzhak Controlled release dosage forms
ITMI20020146A1 (it) * 2002-01-29 2003-07-29 Lyogen Ltd Alendronato monosodico amorfo e processo per la sua preparazione
SK50782006A3 (sk) † 2004-02-26 2007-03-01 Zentiva, A. S. Amorfné formy risedronátu monosodného
EP1571152B1 (en) * 2004-03-03 2007-08-08 CHEMI S.p.A. Amorphous 3-Pyridil-1-Hydroxyethyliden-1,1-Biphosphonic acid monosodium salt and process for the preparation thereof .
CZ297262B6 (cs) * 2004-12-28 2006-10-11 Zentiva, A. S. Trisodná sul kyseliny 4-amino-1-hydroxybutyliden-1,1-bisfosfonové
US20090118238A1 (en) * 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
KR20150053963A (ko) * 2012-09-11 2015-05-19 닥터 레디스 레보러터리즈 리미티드 엔잘루타마이드 다형태 및 그의 제조
JP6404217B2 (ja) 2012-09-11 2018-10-10 メディベイション プロステイト セラピューティクス エルエルシー エンザルタミドの製剤
CA3182565A1 (en) 2015-03-06 2016-09-15 Atea Pharmaceuticals, Inc. .beta.-d-2'-deoxy-2'-.alpha.-fluoro-2'-.beta.-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment
US11447506B2 (en) 2016-05-09 2022-09-20 Anacor Pharmaceuticals, Inc. Crystal forms of crisaborole in free form and preparation method and use thereof
WO2017193914A1 (zh) * 2016-05-09 2017-11-16 苏州科睿思制药有限公司 克立硼罗游离形式的晶型及其制备方法和用途
JP2019518058A (ja) * 2016-06-16 2019-06-27 ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． スピロ−オキシインドール化合物の固体状態形
EP3510021A1 (en) * 2016-09-06 2019-07-17 Indena S.p.A. Solid forms of ingenol 3-(3,5-diethylisoxazole-4-carboxylate) and method for preparing the same
WO2018048937A1 (en) 2016-09-07 2018-03-15 Atea Pharmaceuticals, Inc. 2'-substituted-n6-substituted purine nucleotides for rna virus treatment
US11369579B2 (en) 2016-10-24 2022-06-28 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
US10336679B2 (en) * 2016-10-24 2019-07-02 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
IL288737B (en) * 2017-02-01 2022-09-01 Atea Pharmaceuticals Inc Hemisulfate nucleotide salt for treatment of hepatitis c virus
WO2018178133A1 (en) * 2017-03-30 2018-10-04 Merck Patent Gmbh Solid form of (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)methanol
KR102777452B1 (ko) * 2017-11-22 2025-03-10 아지오스 파마슈티컬스 아이엔씨. N-(4-(4-(시클로프로필메틸)피페라진-1-카르보닐)페닐)퀴놀린-8-술폰아미드의결정 형태
EP3773753A4 (en) 2018-04-10 2021-12-22 ATEA Pharmaceuticals, Inc. TREATMENT OF PATIENTS INFECTED WITH THE HEPATITIS C VIRUS WITH CIRRHOSIS
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
WO2022176017A1 (ja) * 2021-02-16 2022-08-25 大塚製薬株式会社 非晶質体及び当該非晶質体を含む組成物
IL308921A (en) 2021-06-17 2024-01-01 Atea Pharmaceuticals Inc Combination anti-HCV therapy is beneficial

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4304734A (en) * 1980-10-16 1981-12-08 Vysoka Skola Chemicko-Technologicka 6-Amino-1-hydroxyhexylidene diphosphonic acid, salts and a process for production thereof
YU44680B (en) * 1982-07-30 1990-12-31 Glaxo Lab Ltd Process for obtaining very pure amorphous form of cephuroxim axetile
US4922007A (en) 1989-06-09 1990-05-01 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
ATE289199T1 (de) * 1995-06-06 2005-03-15 Merck & Co Inc Formulierungen mit dem wasserfreien mononatriumsalz von alendronat und deren verwendung zur behandlung von knochenkrankheiten
US5853759A (en) * 1996-05-17 1998-12-29 Merck & Co.. Inc. Effervescent alendronate formulation
WO2000012517A1 (en) 1998-08-27 2000-03-09 Teva Pharmaceutical Industries Ltd. Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
EP1135397B1 (en) * 1998-12-10 2003-04-23 Aesgen, Inc. Method for preparation of disodium pamidronate
US6160165A (en) * 1998-12-10 2000-12-12 Aesgen, Inc. Method for preparation of disodium pamidronate
WO2001030788A1 (en) 1999-10-26 2001-05-03 A/S Gea Farmaceutisk Fabrik Novel salts of 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid, their preparation and use

Also Published As

Publication number Publication date
DE60214576T2 (de) 2007-08-30
EP1436303A1 (en) 2004-07-14
DE60214576D1 (de) 2006-10-19
ZA200403024B (en) 2005-03-30
JP4490100B2 (ja) 2010-06-23
JP2005521636A (ja) 2005-07-21
KR20040053186A (ko) 2004-06-23
NZ532292A (en) 2005-07-29
BR0213398A (pt) 2005-01-11
TNSN04067A1 (en) 2006-06-01
CA2463815A1 (en) 2003-04-24
CA2463815C (en) 2009-04-07
RU2004113306A (ru) 2005-10-10
ATE338761T1 (de) 2006-09-15
RU2334751C2 (ru) 2008-09-27
HK1066011A1 (en) 2005-03-11
CL2004001372A1 (es) 2005-05-06
US7112577B2 (en) 2006-09-26
IL161360A0 (en) 2004-09-27
WO2003033508A1 (en) 2003-04-24
ES2271375T3 (es) 2007-04-16
GB2383042A (en) 2003-06-18
PT1436303E (pt) 2006-12-29
GB0125081D0 (en) 2001-12-12
US20040259846A1 (en) 2004-12-23
MXPA04003549A (es) 2004-07-22
AU2002334200B2 (en) 2008-04-03
EP1436303B1 (en) 2006-09-06

Similar Documents

Publication Publication Date Title
ECSP045067A (es) Sales de alendronato farmaceuticamente aceptables en forma amorfa
NO2022032I1 (no) Elvitegravir or a pharmaceutically acceptable salt thereof - Forlenget SPC
NO2023006I1 (no) Tenofovir alafenamide or a salt or solvate thereof, especially tenofovir alafenamide fumarate - forlengelse
ID29504A (id) Benda penyerap
ID29654A (id) Benda penyerap
DK1313714T3 (da) Valsartansalte
ID30522A (id) Benda penyerap
EP1648421A4 (en) ORAL SOLUBLE FILMS
NO20033815L (no) Farmasöytiske salter
ID30418A (id) Benda penyerap
ID29650A (id) Benda penyerap
ID29647A (id) Benda penyerap
ID29678A (id) Benda penyerap
DE60307258D1 (de) Tolterodin-salze
DK1414824T3 (da) Nye antikonvulsive derivatsalte
DE60207081D1 (de) Hybridaufblasvorrichtung
ITBO20000523A0 (it) Occhiale a giorno perfezionato
SE0202132L (sv) En jordbearbetningsenhet
ID29648A (id) Benda penyerap
DE60301895D1 (de) Münzprüfer
ITMI20022547A1 (it) Cassetta di risciacquamento a controllo elettronico per
FI20021053A0 (fi) Menetelmä kolmiulotteisten pintojen kuviointiin
EP1585750A4 (en) NARCISTATIN PRODRUGS
IS6007A (is) Ný morfólínóbensamíðsölt
EP1494584A4 (en) ENDOHEDRAL METALLOFULLEREN CONTRASTANT